相关实验视频

Updated: Sep 15, 2025

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes

Published on: December 20, 2019

MAPT 剪接调节器作为对陶病的治疗策略

M Catarina Silva, Hannah Lindmeier, Paolo Pigini

bioRxiv : the preprint server for biology

|July 14, 2025

概括

研究人员发现了针对MAPT基因的新型拼接调节器化合物 (SMCs). 这些化合物降低有害的4R蛋白,病的标志,并显示神经退行性疾病的治疗潜力.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

病是一种神经退行性疾病,由异常的蛋白积累定义.
目前对病,如前性痴呆症 (FTD-Tau) 的治疗方法有限.
在MAPT基因中的致病变体,特别是影响外10拼接,驱动4R病变.

研究的目的:

发现和描述针对MAPT前mRNA拼接的新型拼接调节器化合物 (SMC).
评估SMCs在4R病的临床前模型中的治疗疗效.

主要方法:

识别促进MAPT外10排除的新型SMC.
在FTD患者衍生的神经元模型中测试P301L或S305N突变的SMC疗效.
评估SMC对4R的表达,的酸化和聚合的影响.
在具有tau-N279K拼接突变的基因替换小鼠模型中的体内验证.

主要成果:

中小企业成功地促进了MAPT的排斥.
治疗减少了4R表达,高酸化 (pTau) 和不溶性聚合物.
在患者衍生模型中,SMC治疗挽救了与tau相关的神经元毒性.
在小鼠模型中,SMC在体内纠正了3R/4R拼接比,并减少了大脑pTau.

结论:

基于SMC的MAPT前mRNA拼接的调制是一种可行的治疗策略,用于4R病症.
这些新型化合物显示出治疗神经退行性疾病的巨大潜力,这些疾病的特征是异常的tau处理.

更多相关视频

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

相关概念视频

Microtubule Associated Proteins (MAPs)

Microtubule Associated Proteins (MAPs)

Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...